NASDAQ:TNYA Tenaya Therapeutics Q3 2026 Earnings Results & Report $0.29 -0.01 (-3.85%) As of 03:26 PM Eastern This is a fair market value price provided by Massive. Learn more. Tenaya Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.08 versus the -$0.1033 consensus estimate, while revenue of $1.70 million topped the $800 thousand estimate by $897 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeAfter Market ClosesConference Call4:00 PM ET Tenaya Therapeutics EPS ResultsActual EPS-$0.08Consensus EPS -$0.1033Beat/MissBeat by +$0.0233One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersTenaya Therapeutics Revenue ResultsActual Revenue$1.70 millionExpected Revenue$800 thousandBeat/MissBeat by +$897.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tenaya Therapeutics Q3 2026 Earnings FAQ Did Tenaya Therapeutics beat earnings estimates for Q3 2026? Tenaya Therapeutics (NASDAQ:TNYA) reported earnings of -$0.08 per share for Q3 2026, beating the consensus estimate of -$0.1033. The report was announced on Wednesday, November 4, 2026. What was Tenaya Therapeutics' revenue for Q3 2026? Tenaya Therapeutics reported revenue of $1.70 million for Q3 2026, against a consensus estimate of $800 thousand. Tenaya Therapeutics Earnings HeadlinesTenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Rated "Moderate Buy" by Wall Street AnalystsNovember 19 at 4:14 AM | americanbankingnews.comFY2026 Earnings Forecast for TNYA Issued By HC WainwrightNovember 9, 2026 | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 20 at 1:00 AM | Weiss Ratings (Ad)H.C. Wainwright Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)November 7, 2026 | theglobeandmail.comTenaya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMTenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 4, 2026 | globenewswire.comSee More Tenaya Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tenaya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenaya Therapeutics and other key companies, straight to your email. Email Address About Tenaya TherapeuticsTenaya Therapeutics (NASDAQ:TNYA) is a clinical-stage biotechnology company focused on developing treatments for heart disease. Based in South San Francisco, California, the company uses genetic medicine and other therapeutic approaches to target the underlying causes of cardiac conditions. Its investigational programs include TN-201, a gene therapy candidate for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. Tenaya has also developed TN-301, an oral small-molecule candidate studied for heart failure with preserved ejection fraction. Tenaya’s candidates are investigational and are not approved medicines. The company was founded in 2016 and focuses its research and development on therapies for serious heart diseases.View Tenaya Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.